Workflow
上海凯宝(300039) - 2016 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2016 was ¥1,497,151,217.58, representing a 7.26% increase compared to ¥1,395,788,575.79 in 2015[15]. - The net profit attributable to shareholders for 2016 was ¥282,606,841.72, a slight increase of 0.34% from ¥281,648,520.79 in the previous year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥288,953,164.97, which is an 8.42% increase from ¥266,512,994.47 in 2015[15]. - The net cash flow from operating activities decreased by 3.73% to ¥314,879,061.21 from ¥327,081,937.18 in 2015[15]. - The total assets at the end of 2016 were ¥2,527,915,724.93, reflecting a 4.17% increase from ¥2,426,668,506.07 at the end of 2015[15]. - The net assets attributable to shareholders increased by 9.71% to ¥2,200,310,644.00 from ¥2,005,509,345.68 in 2015[15]. - The basic earnings per share for 2016 were ¥0.3397, a 0.35% increase from ¥0.3385 in 2015[15]. - The diluted earnings per share also stood at ¥0.3397, consistent with the basic earnings per share[15]. - The weighted average return on equity for 2016 was 13.48%, down from 14.25% in 2015[15]. - The gross profit margin for the industrial segment was 81.25%, with a slight decrease of 0.81% compared to the previous year[56]. Investment and Acquisitions - The company acquired a 20% stake in Shanghai Yizhong Biotechnology Co., and a 25% stake in Shanghai Gebaide Biotechnology Co., becoming the largest shareholder[27]. - The company completed capital increases in Yizhong Biology and Shanghai Gebaide Biotechnology, acquiring a 20% stake and becoming the largest shareholder with 25% respectively, laying the foundation for future expansion in the biopharmaceutical sector[46]. - The company has invested a total of 53,389,339.63 CNY in R&D in 2016, accounting for 3.57% of its operating revenue[65]. - The company has invested RMB 18,268.24 million in the third phase of the "Modernization of Traditional Chinese Medicine and Pharmaceutical Products" project, with a completion rate of 99.80%[87]. - The company completed the acquisition of Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. for RMB 6,721.00 million, achieving 100% utilization of the allocated funds[87]. Research and Development - The company is currently conducting IIb phase clinical trials for its proprietary new drug "Youxinding Capsules" aimed at treating depression[41]. - The company has established an academic workstation with the Chinese Academy of Traditional Chinese Medicine to research the efficacy of Tanreqing injection against antibiotic-resistant bacteria[26]. - The company completed pharmacological and toxicological studies for its core product, Phlegm-Heat Clearing Injection, indicating progress in R&D[63]. - The company is collaborating with various research institutions to enhance the clinical application scope of its products, particularly the Phlegm-Heat Clearing Injection[64]. - The company has a total of 250 products under development, indicating a strong pipeline for future growth[156]. Market and Product Strategy - The company is focusing on expanding its product portfolio, with plans to launch several new products in 2017, including "Silver Yellow Granules" and "Children's Cough and Asthma Granules"[39]. - The company aims to enhance its core competitiveness through innovation and strategic expansion in the modern biopharmaceutical field[30]. - The company is actively collaborating with external research institutes to enter the traditional Chinese medicine granule market, aiming to establish national quality standards[102]. - The company will enhance its sales model and marketing efforts to increase brand influence and market share, particularly in the generic drug market[102]. - The company’s brand "Shanghai Kaibao" has been recognized as a famous trademark in Shanghai, enhancing brand influence and market competitiveness[35]. Corporate Governance and Compliance - The company has complied with all commitments made during the reporting period, with no violations found[119]. - The company has maintained a good integrity status, with no significant debts or court judgments unfulfilled during the reporting period[130]. - The audit firm, Lixin Certified Public Accountants, has been retained for 9 years, with an audit fee of 550,000 yuan for the reporting period[128]. - The company has not faced any major litigation or arbitration matters during the reporting period[128]. - The company has implemented a restricted stock incentive plan to enhance employee motivation and competitiveness, which was approved by the China Securities Regulatory Commission in 2014[131]. Employee and Management - The total number of employees in the company is 1,684, with 1,241 in the parent company and 443 in major subsidiaries[196]. - The company has implemented a competitive compensation system, including fixed salaries, performance bonuses, and comprehensive welfare benefits[197]. - Training programs have been organized for various employee levels, including management and sales personnel, to enhance skills and team cohesion[199]. - The company has established an equity incentive plan to align employee interests with company performance[197]. - The total remuneration paid to the board of directors, supervisors, and senior management for the year 2016 amounted to 4.325 million yuan[194]. Financial Management - The company reported a net increase in cash and cash equivalents of -226,671,214.34 CNY, a decline of 374.32% compared to the previous year[68]. - The company has no capitalized R&D expenditures, maintaining a 0.00% capitalization rate for the past three years[65]. - The company has entrusted 7,000 million yuan in cash management to ICBC Credit Suisse Investment Management, with an expected return of 318 yuan for the reporting period[149]. - The company also entrusted 4,000 million yuan in cash management to the Shanghai branch of the Industrial and Commercial Bank of China, with an actual return of 86 yuan for the reporting period[149]. - The company reported no overdue principal or interest during the reporting period[152]. Social Responsibility - The company’s social responsibility report has been published, highlighting its commitment to social and environmental responsibilities[155]. - The company’s total social contributions, including donations and services, amounted to 121.8 million yuan[156]. - The company has been recognized for its environmental management practices, having passed the ISO14001 environmental management system certification[156]. - The company invested 134.01 million yuan in environmental protection efforts and 339.29 million yuan in employee training and development[156]. Shareholder Information - The company has implemented a cash dividend policy, distributing RMB 1 per 10 shares to shareholders based on a total share capital of 829.55 million shares[110]. - The company proposed a profit distribution plan for 2016, with a capital reserve increase of 3 shares for every 10 shares held, based on a total share capital of 824,226,000 shares after deducting repurchased shares[113]. - The total cash dividend for 2016 is 0.00 yuan, with a cash dividend ratio of 0.00% of the total profit distribution[118]. - The company’s total share capital as of December 31, 2016, was 82,943.16 million shares, after accounting for repurchased shares[116]. - The total number of common shareholders at the end of the reporting period was 38,837, an increase from 38,347 in the previous month[171].